As orphan drug costs continue to rise, MedImpact Healthcare Systems Drug Information Pharmacist Steven Jung says payers are stepping to the plate in an effort to better manage pricing and utilization of treatments, Managed Healthcare Executive reports.
Jung, who spoke Wednesday during the Academy of Managed Care Pharmacy’s annual meeting in Boston, says U.S. Food and Drug Administration approvals for orphan drugs has increased from less than 30 in 2013 to about 70 in 2017.
Due to the significant costs associated with orphan drugs, payers have adopted some changes to benefit designs to deliver more robust cost and treatment solutions.
Payers, among other things, are looking into:
- Applying formulary restrictions in addition to specialty tiers;
- Transitioning from copyaments to co-insurance; and
- Prior authorization.
To read the full report on Managed Healthcare Executive, click here.